Halozyme Therapeutics Announces Nasdaq Global Market Listing Approval

Share This

04/30/2007
Halozyme Shares Expected to Commence Trading on May 10, Under the Ticker Symbol HALO
SAN DIEGO, April 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Halozyme Therapeutics, Inc. (Amex: HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Nasdaq has approved the Company's application for listing on the Nasdaq Global Market. Halozyme anticipates that its common stock will begin trading under the ticker symbol "HALO" on May 10, 2007. Halozyme's stock will continue to trade on the American Stock Exchange under the symbol "HTI.R" until the effective date.

"We are thrilled to be listing on the Nasdaq Global Market, which marks another important achievement for Halozyme," said Jonathan Lim, MD, President and CEO of Halozyme. "Trading on Nasdaq benefits our shareholders because it will provide greater visibility of Halozyme within the investment community and potentially increase the liquidity of our stock. We were very fortunate to have had the opportunity to trade on the Amex for the last two-and-a-half years, and would like to extend our gratitude to the highly committed people working at the Amex."

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company has received FDA approval for two products: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the increase in liquidity of its common stock and the anticipated first trading date of the Company's common stock on the Nasdaq Global Market) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Halozyme Contact               Investor Relations Contact
    David A. Ramsay                Don Markley
    Chief Financial Officer        Lippert/Heilshorn & Associates
    (858) 794-8881                 (310) 691-7100
    dramsay@halozyme.com           dmarkley@lhai.com

                                   Media Contacts
                                   Karen Sparks / Joleen Schultz
                                   Mentus
                                   (858) 455-5500, x275/x215
                                   karen@mentus.com
                                   jschultz@mentus.com

SOURCE Halozyme Therapeutics, Inc.

David A. Ramsay, Chief Financial Officer of Halozyme Therapeutics, Inc.,
+1-858-794-8881, dramsay@halozyme.com; or Investors, Don Markley of Lippert/Heilshorn
& Associates, +1-310-691-7100, dmarkley@lhai.com, for Halozyme Therapeutics,
Inc.; or Media, Karen Sparks, ext.275, karen@mentus.com, or Joleen Schultz, ext. 215,
jschultz@mentus.com, both of Mentus, +1-858-455-5500, for Halozyme Therapeutics, Inc.

http://www.prnewswire.com

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok